Vyne Therapeutics Inc (VYNE) FinancialsVYNEFinancialVyne Therapeutics Inc

Vyne Therapeutics Inc (VYNE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product sales, net, accounting for 88.1% of total sales, equivalent to $2.02M. Another important revenue stream is Royalty revenues. Understanding this composition is critical for investors evaluating how VYNE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Vyne Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4437.21%, while the net margin is -4168.60%. These profitability ratios, combined with a Return on Equity (ROE) of -63.16%, provide a clear picture of how effectively VYNE converts its operational activities into shareholder value.

In the context of the broader market, VYNE competes directly with industry leaders such as CLRB and AYTU. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, VYNE's gross margin of 100.00% stands against CLRB's N/A and AYTU's 55.10%. Such benchmarking helps identify whether Vyne Therapeutics Inc is trading at a premium or discount relative to its financial performance.

No financial data available for the latest quarter.